Lecanemab: FDA Approved for Early Alzheimer’s Disease

On July 06, 2023: FDA announced the approval of Leqembi (Lecanemab) for adult patients with early Alzheimer’s Disease or mild cognitive impairment.

Psychiatry Education Forum Academy’s Updates have summarized this medication in the following sections:

WATCH DISCUSSION:

HERE IS ONE SLIDE FROM THIS PRESENTATION:

HOW TO DOSE?

References:

WATCH FOLLOWING DISCUSSION SERIES

[FOR PEFA MEMBERS]

GERIATRIC PSYCHIATRY: NEUROCOGNITIVE DISORDERS

Non-Pharmacological treatment options for the management of behavioral symptoms in dementia

Which antipsychotic is FDA Approved for the management of agitation associated with dementia in Alzheimer’s Disease?
Which antipsychotics is not recommended as a first-line agent for non-emergent use in patients with dementia?
when is haloperidol indicated or appropriate?
which second generation antipsychotics to prescribe?
How do antipsychotics compare with black box warning of increased mortality?
Where does APA guidelines stand on role of quetiapine in patients with dementia?
How long to continue this treatment for?
How often will you monitor these patients after discontinuation of medications?
When will you continue medications for > 4 months ?

30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
Clinical Case Discussions: Discussions of clinical cases from our daily clinical practice.
Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
Goal: is to have all important clinically relevant topics in one place for ease of access.